Evidence map›Paper›PMID 41781696›Full record

ArticleCellular & molecular immunology2026

Oncolytic virus M1 reinvigorates CD8

Yu Han, Cui Guo, Chaoxin Chen, Wenzhuo Yang, Honghui Li, Changjia He, Jialin Deng, Zhijie Chen, Wenfeng Liu, Jiehong Chen and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Yu Han *Department of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Cui Guo *Department of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Chaoxin Chen *Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Wenzhuo Yang *Department of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Honghui LiDepartment of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Changjia HeDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jialin DengDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhijie ChenDepartment of Neurosurgery, The Third Affiliated Hospital of Sun Yat-sen University Lingnan Hospital, Guangzhou, China.
Wenfeng LiuDepartment of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Jiehong ChenDepartment of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Yingqian ZhongDepartment of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Caixin YanDepartment of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Cuiying XuDepartment of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Xuanming LiangDepartment of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Sheng ZhongDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Furong ChenDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Depei LiDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Cong LiThe Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Wanming HuDepartment of Pathology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhenghe ChenDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yonggao MouDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhongping ChenDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Guangmei YanDepartment of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Michael LimDepartment of Neurosurgery, Stanford School of Medicine, Palo Alto, CA, USA.
Wenbo ZhuDepartment of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. zhuwenbo@mail.sysu.edu.cn.
Ke SaiDepartment of Neurosurgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China. saike@sysucc.org.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82373284National Natural Science Foundation of China (National Science Foundation of China) 82373903
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is a lethal primary brain cancer with limited treatment options. Systemic and local immunosuppression induced by GBMs contributes to malignancy aggressiveness and resistance to immune checkpoint blockade (ICB) therapy. Herein, we demonstrated that a novel oncolytic virus, M1 (OVM), reversed GBM-driven systemic immunosuppression and promoted T lymphocyte infiltration within the tumor microenvironment (TME). Intravenous administration of OVM suppressed glioma progression in a spleen-dependent manner. Mechanistically, OVM enhanced B-cell-T-cell interactions in the spleen through the formation of immune synapses. A subset of B cells positive for bone marrow stromal cell antigen 2 (Bst2) was enriched in the splenic marginal zone following OVM treatment and exhibited superior capacity for antigen cross-presentation. These splenic Bst2

Indexed as

B-LymphocytesBrain NeoplasmsCD8-Positive T-LymphocytesCross-PrimingGlioblastomaOncolytic VirotherapyOncolytic VirusesSpleenAnimalsBone Marrow Stromal Antigen 2Cell Line, TumorHumansMiceMice, Inbred C57BLTumor MicroenvironmentBone Marrow Stromal Antigen 2Antigen cross-presentationB cellGliomaOncolytic virus

Identifiers

PMID41781696
PMCPMC13035954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.